Jazz Pharmaceuticals PLC- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Jazz Pharmaceuticals PLC 公司

Jazz Pharmaceuticals PLC 是一家生物技术公司。该公司致力于为患有严重疾病的人开发药物。该公司的主要营销产品包括 Xywav（钙、镁、钾和钠羟基丁酸盐）口服溶液、Xyrem（钠羟基丁酸盐）口服溶液、Epidiolex（大麻二酚）口服溶液、Rylaze（重组欧文氏菌天冬酰胺酶-rywn）、Zepzelca（lurbinectedin）、Defitelio（去纤维苷酸钠）和 Vyxeos（柔红霉素和阿糖胞苷）注射用脂质体。Xywav（钙、镁、钾和钠羟基丁酸盐）口服溶液产品用于治疗 7 岁及以上发作性睡病患者的猝倒症或白天过度嗜睡 (EDS)。 Xyrem（羟基丁酸钠）口服溶液产品用于治疗 7 岁及以上发作性睡病患者的猝倒症或 EDS。Defitelio（去纤维苷酸钠）产品用于治疗肝静脉闭塞症 (VOD)。

Jazz Pharmaceuticals PLC简介



公司代码JAZZ

公司名称Jazz Pharmaceuticals PLC

上市日期Jan 18, 2012

CEOMs. Renee D. Gala

员工数量2800

证券类型Ordinary Share

年结日Jan 18

公司地址Fifth Floor, Waterloo Exchange

城市DUBLIN

上市交易所NASDAQ Global Select Consolidated

国家Ireland

邮编- -

电话35316347800

网址https://www.jazzpharma.com/

公司代码JAZZ

上市日期Jan 18, 2012

CEOMs. Renee D. Gala

Jazz Pharmaceuticals PLC公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

307.81K

-1.76%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.20K

+64.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

29.39K

+6.15%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

Dr. Norbert G. Riedel, Ph.D.

Independent Director

13.92K

+13.93%

Ms. Anne O'Riordan

Independent Director

12.77K

+15.38%

Mr. Rick E. Winningham

Lead Independent Director

10.66K

+19.00%

名称

名称/职务

职务

持股

持股变动

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

307.81K

-1.76%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.20K

+64.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

29.39K

+6.15%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Xywav

415.32M

39.72%

Epidiolex/epidyolex

251.73M

24.07%

Rylaze

100.66M

9.63%

Zepzelca

74.54M

7.13%

High-sodium oxybate AG royalty revenue

54.14M

5.18%

其他

149.32M

14.28%

地区USD

名称

营收

占比

United States

936.28M

89.54%

Europe

82.76M

7.91%

All Others

26.67M

2.55%

业务

地区

业务USD

名称

营收

占比

Xywav

415.32M

39.72%

Epidiolex/epidyolex

251.73M

24.07%

Rylaze

100.66M

9.63%

Zepzelca

74.54M

7.13%

High-sodium oxybate AG royalty revenue

54.14M

5.18%

其他

149.32M

14.28%

股东统计

更新时间: 10月16日周四

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

10.00%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.21%

Capital World Investors

4.19%

Dimensional Fund Advisors, L.P.

4.18%

其他

68.80%

持股股东

占比

The Vanguard Group, Inc.

10.00%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.21%

Capital World Investors

4.19%

Dimensional Fund Advisors, L.P.

4.18%

其他

68.80%

股东类型

持股股东

占比

Investment Advisor

52.52%

Investment Advisor/Hedge Fund

34.31%

Hedge Fund

8.96%

Research Firm

3.43%

Individual Investor

3.07%

Pension Fund

2.79%

Venture Capital

1.89%

Bank and Trust

0.96%

Sovereign Wealth Fund

0.12%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

1191

64.20M

105.84%

-4.58M

2025Q2

1199

63.76M

105.11%

-6.47M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

2023Q2

1197

61.00M

95.34%

-4.11M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

6.07M

10%

+73.43K

+1.22%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.22M

8.61%

+11.23K

+0.22%

Jun 30, 2025

LSV Asset Management

2.55M

4.21%

+87.58K

+3.55%

Jun 30, 2025

Capital World Investors

2.54M

4.19%

+616.73K

+31.99%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

2.54M

4.18%

+209.41K

+8.99%

Jun 30, 2025

State Street Investment Management (US)

1.94M

3.19%

-31.20K

-1.59%

Jun 30, 2025

EcoR1 Capital, LLC

1.71M

2.81%

--

Jun 30, 2025

Fuller & Thaler Asset Management Inc.

1.63M

2.69%

+297.95K

+22.39%

Jun 30, 2025

JP Morgan Asset Management

1.55M

2.55%

+46.92K

+3.12%

Jun 30, 2025

Columbia Threadneedle Investments (US)

1.54M

2.54%

+186.67K

+13.80%

Jun 30, 2025

持股ETF



更新时间: 11月2日周日

机构名称

占比

LSV Disciplined Value ETF

27.6%

Cambria Cannabis ETF

5.46%

iShares U.S. Pharmaceuticals ETF

2.95%

Invesco Pharmaceuticals ETF

2.86%

First Trust Health Care Alphadex Fund

2.63%

SPDR S&P Pharmaceuticals ETF

2.5%

First Trust NASDAQ Pharmaceuticals ETF

2.28%

Abacus FCF International Leaders ETF

2.02%

Alger Russell Innovation ETF

2%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.87%

LSV Disciplined Value ETF

占比27.6%

Cambria Cannabis ETF

占比5.46%

iShares U.S. Pharmaceuticals ETF

占比2.95%

Invesco Pharmaceuticals ETF

占比2.86%

First Trust Health Care Alphadex Fund

占比2.63%

SPDR S&P Pharmaceuticals ETF

占比2.5%

First Trust NASDAQ Pharmaceuticals ETF

占比2.28%

Abacus FCF International Leaders ETF

占比2.02%

Alger Russell Innovation ETF

占比2%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.87%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据